Head to Head Comparison: MariMed (MRMD) & The Competition

MariMed (OTC:MRMD) is one of 55 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its competitors? We will compare MariMed to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.

Valuation and Earnings

This table compares MariMed and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MariMed	$148.60 million	-$16.03 million	-2.61
MariMed Competitors	$310.32 million	-$49.81 million	-1.74

MariMed’s competitors have higher revenue, but lower earnings than MariMed. MariMed is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

0.2% of MariMed shares are owned by institutional investors. Comparatively, 15.8% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 19.0% of MariMed shares are owned by company insiders. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for MariMed and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MariMed	0	0	0	1	4.00
MariMed Competitors	289	565	1080	86	2.48

As a group, “Medicinals & botanicals” companies have a potential upside of 81.97%. Given MariMed’s competitors higher possible upside, analysts clearly believe MariMed has less favorable growth aspects than its competitors.

Profitability

This table compares MariMed and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MariMed	-8.95%	1.58%	0.53%
MariMed Competitors	-38.94%	-24.68%	-6.33%

Risk and Volatility

MariMed has a beta of 3.15, suggesting that its share price is 215% more volatile than the S&P 500. Comparatively, MariMed’s competitors have a beta of 1.30, suggesting that their average share price is 30% more volatile than the S&P 500.

Summary

MariMed beats its competitors on 7 of the 13 factors compared.

MariMed Company Profile

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.